Measuring pre-and post-dose vancomycin levels—time for a change?

References

1. “Targocid” injection data sheet; 1989
2. Geraci J. E., Heilman F. R., Nichols D. R., Wellman W. E. Antibiotic therapy of endocarditis, VII. Vancomycin for acute micrococcal endocarditis: preliminary report. Mayo Clin Proc 1958; 33:172–181
   [Google Scholar]
3. Ackerman B. H., Vanier A. M., End E. B. Analysis of vancomycin time kill studies with Staphylococcal species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36:1766–1769
   [Google Scholar]
4. Flandrois J. P., Fardel G., Carret G. Early stages of in-vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus . Antimicrob Agents Chemother 1988; 32:454–457
   [Google Scholar]
5. Cantu T. G., Yamanaka-Yuen N. A., Leitman P. S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:533–543
   [Google Scholar]
6. Geraci J. E. Vancomycin. Mayo Clin Proc 1977; 52:631–634
   [Google Scholar]
7. Farber B. F., Moellering R. C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23:138–141
   [Google Scholar]
8. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus . Ann Intern Med 1982; 97:344–350
   [Google Scholar]
9. Schaad U. B., McCracken G. H., Nelson J. D. Clinical pharma cology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96:119–126
   [Google Scholar]
10. Moellering R. C. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14: Suppl D 43–52
    [Google Scholar]
11. Matzke G. R., McGory R. W., Halstenson C. E., Keane W. F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433–437
    [Google Scholar]
12. Moellering R. C., Krogstad D. J., Greenblatt D. J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343–346
    [Google Scholar]
13. Lake K. D., Peterson C. D. Comparison of vancomycin serum concentrations obtained with standard vs. individualised dosing regimens. Drug Intell Clin Pharm 1985; 19:459 (Abstract)
    [Google Scholar]
14. Rybak M. J., Boike S. C. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm 1986; 20:64–68
    [Google Scholar]
15. “Vancocin” CP data sheet Sept 1991 VA.IM
    [Google Scholar]
16. Rotschafer J. C., Crossley K., Zaske D. E., Mead K., Sawchak R. J., Solem L. D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22:391–394
    [Google Scholar]
17. Krogstad D. J., Moellering R. C., Greenblatt D. J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980; 20:197–201
    [Google Scholar]
18. Saunders N. J. Why monitor peak vancomycin concentrations?. Lancet 1994; 344:1748–1750
    [Google Scholar]
19. Edwards D. J., Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clinical Pharmacy 1987; 6:652–654
    [Google Scholar]